An update on extracellular vesicles in hematologic disorders: molecular mediators, clinical biomarkers, and emerging therapeutics
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10971-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Chunlei Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient department, affiliated hospital of Beihua University, Jilin, 132011, Jilin, China. 545292969@qq.com. Hauptthemen laut MEDLINE: Extracellular Vesicles, Hematologic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 115 Literaturangaben.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are nanosized particles secreted by various cell types. These vesicles play vital roles in intercellular communication and carry diverse cargos of bioactive molecules. In hematological malignancies, EV-associated miRNAs (e.g., miR-21, miR-155) and proteins (e.g., CD30, TGF-β1) act as non-invasive biomarkers for leukemia and lymphoma, surpassing traditional methods in sensitivity. In myelodysplastic syndromes (MDS), EVs containing dysregulated miR-10a and miR-15a are linked to disease progression. Prognostically, EV levels and cargo composition help predict treatment response and relapse risk, as demonstrated in acute myeloid leukemia (AML), where increased miR-10b in EVs relates to poorer survival. Beyond cancers, EVs also contribute to coagulation disorders, sickle cell disease, and other hematological conditions by modifying cellular interactions and signaling pathways. The diagnostic potential of EVs lies in their disease-specific molecular content. Therapeutically, EVs present advantages like low immunogenicity and targeted delivery capabilities. Engineered EVs loaded with CRISPR/Cas9 or tumor-suppressor miRNAs (e.g., miR-15a) show promise for gene editing and cancer treatment. Challenges include scalable production, standardization, and minimizing off-target effects, but innovations such as synthetic EV mimetics and hybrid vesicles aim to overcome these issues. They serve as biomarkers for early detection and prognosis, offering valuable insights into disease mechanisms. Their unique physical and chemical properties, along with their pro-tumor effects, make them promising biomarkers, therapeutic targets, and drug delivery platforms. By summarizing their roles in disease pathogenesis and clinical applications, this work emphasizes the significance of EVs in enhancing understanding and treatment of hematological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Outpatient department, affiliated hospital of Beihua University, Jilin, 132011, Jilin, China. 545292969@qq.com.
- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Faculty of Allied Medicine, Department of Hematology and Medical Laboratory Sciences, Kerman University of Medical Sciences, Kerman, Iran.
- Student Research Committee, Department of Medical Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
- Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), WHO Collaborating Centre (WHOCC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Song, C., Noormohamadi, H., Soleimani Samarkhazan, H., Pilehvari, N., Jafari, Z., Maleknia, M., Taghinejad, Z., & Kheyrandish, S. (2025). An update on extracellular vesicles in hematologic disorders: molecular mediators, clinical biomarkers, and emerging therapeutics. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10971-9
Vancouver
Song C, Noormohamadi H, Soleimani Samarkhazan H, Pilehvari N, Jafari Z, Maleknia M, et al. An update on extracellular vesicles in hematologic disorders: molecular mediators, clinical biomarkers, and emerging therapeutics. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10971-9
BibTeX
@article{Song2025,
author = {Song, Chunlei and Noormohamadi, Hanieh and Soleimani Samarkhazan, Hamed and Pilehvari, Niloofar and Jafari, Zahra and Maleknia, Mohsen and Taghinejad, Zahra and Kheyrandish, Setare},
title = {An update on extracellular vesicles in hematologic disorders: molecular mediators, clinical biomarkers, and emerging therapeutics},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10971-9}
}
EUVIMED